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Plasma rich in growth factors (PRGF) is a subtype of platelet-rich plasma that has being
employed in the clinic due to its capacity to accelerate tissue regeneration. Autologous
PRGF has been used in ophthalmology to repair a range of retinal pathologies with some
efficiency. In the present study, we have explored the role of PRGF and its effect on
microglial motility, as well as its possible pro-inflammatory effects. Organotypic cultures
from adult pig retinas were used to test the effect of the PRGF obtained from human as well
as pig blood. Microglial migration, as well as gliosis, proliferation and the survival of retinal
ganglion cells (RGCs) were analyzed by immunohistochemistry. The cytokines present in
these PRGFs were analyzed by multiplex ELISA. In addition, we set out to determine if
blocking some of the inflammatory components of PRGF alter its effect on microglial
migration. In organotypic cultures, PRGF induces microglial migration to the outer nuclear
layers as a sign of inflammation. This phenomenon could be due to the presence of several
cytokines in PRGF that were quantified here, such as themajor pro-inflammatory cytokines
IL-1β, IL-6 and TNFα. Heterologous PRGF (human) and longer periods of cultured (3 days)
inducedmore microglia migration than autologous porcine PRGF. Moreover, the migratory
effect of microglia was partially mitigated by: 1) heat inactivation of the PRGF; 2) the
presence of dexamethasone; or 3) anti-cytokine factors. Furthermore, PRGF seems not to
affect gliosis, proliferation or RGC survival in organotypic cultures of adult porcine retinas.
PRGF can trigger an inflammatory response as witnessed by the activation of microglial
migration in the retina. This can be prevented by using autologous PRGF or if this is not
possible due to autoimmune diseases, by mitigating its inflammatory effect. In addition,
PRGF does not increase either the proliferation rate of microglial cells or the survival of
neurons. We cannot discard the possible positive effect of microglial cells on retinal
function. Further studies should be performed to warrant the use of PRGF on the nervous
system.
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INTRODUCTION
Platelet preparations, including platelet-rich plasma (PRP),
contain high concentrations of growth factors that promote
regeneration, and they are generally considered to be safe to use
and typically inexpensive to obtain (Marx et al., 1998; Wang and
Avila, 2007; Cole et al., 2010; Dhurat and Sukesh, 2014). Plasma
rich in growth factors (PRGF) is a subtype of P-PRP (pure
platelet-rich plasma), which are preparations without
leukocytes and with a low-density fibrin network that may
stimulate tissue regeneration (Dohan Ehrenfest et al., 2014).
Autologous PRGF has been approved for clinical use in the
European Community and by the U.S. Food and Drug
Administration (FDA: Hayashi and Takagi, 2015; Cui et al.,
2017; Osborne et al., 2018), and it has commonly been employed
in ophthalmology in the form of eye drops (Lopez-Plandolit
et al., 2010; Lopez-Plandolit et al., 2011; Merayo-Lloves et al.,
2015; Sanchez-Avila et al., 2018). In addition, pilot studies are
currently being carried out regarding the use of PRGF in retinal
surgery to treat persistent macular holes (Arias et al., 2019) and
autologous platelet injections have been used to treat recurrent
retinal detachment (Nadal et al., 2012). However, the full range
of responses that could be triggered by PRGF are not fully
understood.
The PRGF used in the clinic is often autologous, obtained from
the patient’s own blood, although human PRGF has also been
used in studies with mice (Anitua et al., 2013; Anitua et al., 2014b;
Anitua et al., 2015a). This fact could be important to establish
therapies for patients suffering from autoimmune diseases whose
autologous PRGF may contain auto-antibodies (Anitua et al.,
2014a), or for patients in whom their own PRGF is not as effective
as expected due to variations in specific factors (Vahabi et al.,
2015). Thus, we set out here to assess the effect of PRGF of two
different origins. The model animal selected for this study was the
pig, as the porcine retina is the most similar to the human retina
among large mammals (Prince and Ruskell, 1960; Vecino and
Sharma, 2011).
In the central nervous system (CNS), PRGF can interact with
glial cells, promoting their survival, proliferation and
differentiation (O’kusky et al., 2000; Jin et al., 2002; Anitua
et al., 2009; Anitua et al., 2014b), as well as influencing
inflammatory processes (Anitua et al., 2015a). Microglia are
one of the three main types of glial cells in the mammalian
retina and they form a population of resident macrophages within
the CNS that are not only involved in immune responses but also,
that participate in the development and maintenance of neural
networks. Thus, microglia represent an important nexus between
the neurological and immunological activity in the CNS
(Fernandes et al., 2014; Gertig and Hanisch, 2014; Vecino
et al., 2016; Davis et al., 2017).
Microglia are quiescent in the normal adult retina, exhibiting
a characteristic ramified morphology that allows them to scan
their environment and phagocytose cell debris. In these
conditions, resident microglia are strictly limited to the inner
retinal layers, mainly populating the plexiform layers (Lee et al.,
2008; Buschini et al., 2011). However, microglia become
activated in response to neuronal injury or immunological
stimuli (Streit et al., 1988; Kreutzberg, 1996; Block and
Hong, 2005) and in the retina, the activation of resident
microglia drives their migration to the outer retinal layers,
where they transform into activated, ameboid, full-blown
phagocytes that interact with infiltrating blood cells
(Karlstetter et al., 2015). All types of neuroinflammation
produce chronic microglial activation, including ocular
inflammation, which is coupled to the release of
inflammatory mediators and phagocytosis (Block and Hong,
2005). Thus, activated microglia fulfill an important role in the
initiation and propagation of neurodegenerative processes
(Madeira et al., 2015a). Given the location and size of
microglia, and the fact that they may migrate to the outer
layers of the retina in an inflammatory explant model, these
cells resemble the hyperreflective dots that can be seen in the
ONL and external limiting membrane in uveitis and ocular
inflammation when studied by optical coherence tomography
(OCT) in vivo (Coscas et al., 2013; Vujosevic et al., 2013;
Pakzad-Vaezi et al., 2014). These dots are a sign of disease
progression and prognosis, such that the in vivo imaging of
microglia by OCT may increase its diagnostic value in clinical
ophthalmology, and this can be studied in the model of
organotypic retinal culture used here. Therefore, we analyzed
the inflammatory response to PRGF by assessing microglial cell
migration in retinal explants exposed to PRGF and by
characterizing the inflammatory cytokines it contains.
Moreover, the inflammatory response to PRGF was
compromised by heat inactivation, by adding dexamethasone
(Dex) as an anti-inflammatory drug, or by adding antibodies
against some pro-inflammatory cytokines to the PRGF in order
to study whether these manipulations inhibit the inflammatory
response of microglia to PRGF.
In relation to the inflammatory processes, macroglia also
respond to and undergo reactive gliosis. Retinal macroglia
include Müller cells and astrocytes, the former extending
across the thickness of the retina to provide structural
stability and maintaining close contact with the majority of
retinal neurons. Astrocytes are mostly located in the nerve
fiber layer and they accompany the blood vessels. Both these
cell types provide trophic factors to neurons, which promote
cell survival and repair, as well as maintaining retinal
homeostasis and that of the blood–retina barrier
(Bringmann and Reichenbach, 2001; Bringmann et al., 2006;
Reichenbach and Bringmann, 2013; Vecino et al., 2016).
Reactive gliosis is a response to a multitude of insults and
disorders, altering the thickening and enlargement of Müller
cells, and of astrocyte processes. Typical features of macroglial
gliosis involve cellular hypertrophy, such as the up-regulation
of intermediate filament (IF) expression (e.g., glial fibrillary
acidic protein -GFAP) or increased rates of proliferation
(Barres, 2008; Vecino et al., 2016). Thus, the rate of glial
cell proliferation may be altered in the presence of PRGF as
it is known to contain growth factors that accelerate glial cell
proliferation (O’kusky et al., 2000; Jin et al., 2002; Anitua et al.,
2009; Anitua et al., 2014b), such as platelet-derived growth
factor (PDGF), fibroblast growth factor (FGF), epidermal
growth factor (EGF) and nerve growth factor (NGF: Orive
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et al., 2009; Anitua et al., 2010). Therefore, as PRGF may
induce an inflammatory response in the retina, we set out to
determine whether PRGF stimulates gliosis and the
proliferation of glial cells in retinal explants. In cultured
Müller cells, we have demonstrated the capacity of PRGF to
increase the number of the Müller glia (Ruzafa et al., 2021).
Finally, an intranasal delivery system of PRGF has been
designed in order to reverse the neurodegeneration in a
transgenic mouse model of Alzheimer’s disease (AD: Suga
et al., 2014; Osborne et al., 2018), based on PRGF acting as a
neurotrophic factor promoting neuronal survival in the presence
of amyloid-β (Suga et al., 2014; Pan et al., 2019). The retina, as
part of the CNS, has a limited capacity for repair after disease or
lesion, and retinal lesions cause the death of retinal ganglion cells
(RGCs), the neurons responsible for the communication between
the eye and brain. These lesions might result in irreversible
blindness (Newman and Reichenbach, 1996; Garcia et al.,
2002), as occurs in the case of glaucoma (Glovinsky et al.,
1991; Wygnanski et al., 1995), axonal degeneration (Newman
and Reichenbach, 1996) or ischemia (Selles-Navarro et al., 1996;
Nadal-Nicolas et al., 2012). However, RGCs can recover their
regenerative capacities in appropriate environments (Fischer and
Reh, 2003; Berry et al., 2008). Thus, and based on the potential
neuroprotective properties of PRGF, we finally set out to
determine whether PRGF affects the survival of RGCs.
In summary, we examined here the effect of PRGF of two
different origins in organotypic retinal cultures, analyzing
microglia migration, gliosis, proliferation and RGC survival.
The inflammatory cytokines in PRGF were also quantified




To analyze the effect of PRGF in the retina, we used retinal
explants to assess the inflammatory effect of PRGF and
the migration of microglial cells in these explants (see
Figure 1). In addition, the effect of PRGF on the
proliferation, gliosis and survival of RGCs was also assessed
in these organotypic retinal cultures, as were the cytokines
present in the PRGF.
Porcine Samples
Adult porcine eyes (n  20) and blood (n  5) were obtained
from a local slaughterhouse and the eyes were transported to
the laboratory on ice in CO2-independent medium (Life
Technologies, Carlsbad, CA, USA) plus 0.1% gentamicin.
The retinas were dissected out of the eyes 1–2 h after
enucleation. All animal experimentation adhered to the
ARVO Statement for the Use of Animals in Ophthalmic
and Vision Research.
Human and Pig Plasma Rich in Growth
Factors
Qualified personnel carried out this research and approval for the
study was obtained in strict accordance with the tenets of the
Helsinki Declaration on Biomedical Research Involving Human
Subjects. Before blood collection, signed informed consent was
obtained from all the subjects once the nature of the study and the
possible consequences of the study had been explained. Human
blood samples were obtained through antecubital vein puncture
and PRGF was obtained as described previously (Suga et al.,
2014), with some minor modifications. Briefly, human (n  3)
and porcine (n  5) blood was collected into 5 ml tubes
containing 3.8% (wt/vol) sodium citrate. Samples were
centrifuged at 460 g for 8 min at room temperature and the
plasma fraction containing platelets but not the buffy coat and
erythrocytes were separated. The plasma fraction (1 ml) was
reconstituted for 1 h at 34°C with 50 µL calcium chloride
(Braun Medical, Melsungen, Germany) in glass tubes, and the
supernatant released was collected after centrifugation at 460 g
for 15 min. Finally, part of the total volume of the PRGF obtained
was heat-inactivated at 56°C for 60 min following a protocol
published previously (Anitua et al., 2014a), and both the samples
(PRGF and inactive PRGF) were filtered through a filter pore size
of 0.2 mm (Fisher Scientific, Madrid, Spain), aliquoted and stored
at −80°C.
Organotypic Retinal Cultures
Under aseptic conditions, each pig eyeball was immersed in
70% ethanol, washed in clean CO2−independent medium and
FIGURE 1 | Scheme to analyze the properties of the PRGF in
organotypic cultures of adult porcine retinas. First, PRGF was obtained from
human and porcine blood by separation and plasma extraction.
Subsequently, the effect of the PRGF was evaluated on retinal explants
by assessing microglial activation, gliosis and proliferation, and RGC survival.
In addition, the cytokines in the human and porcine PRGF was quantified
using a Q-plex assay. Finally, given the implication of PRGF in promoting
inflammation, the effects of exposing the explants exposed to dexamethasone
(Dex), cytokines (Cyt: IL-1β, IL-6 and TNFα) or cytokines plus antibodies raised
against these cytokines (anti-cyt: anti-IL-1β, IL-6 and TNFα) were also
evaluated. Finally, we examined the effect of heat-inactivated PRGF, as well as
PRGF combined with Dex or anti-cyt, analyze their effects on microglial
migration.
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neuroretinal explants were obtained as described previously
(Del Rio et al., 2011). After removing the lens and the vitreous
humor, the entire retina was detached by paint brushing
and cutting the optic nerve. Using an 8 mm diameter
dissecting trephine, five retinal explants were obtained
from the middle part of the retina of each eye, at the same
distance from the optic nerve and excluding the larger vessels.
The explants were transferred to cell culture inserts (0.45 μm
pore, 12 mm diameter: Merck Millipore, Darmstadt,
Germany) with the photoreceptor layer facing the
membrane, and they were cultured in Neurobasal A
medium (Life Technologies, Carlsbad, CA, USA)
supplemented with 1% L-glutamine (2 mM: Life
Technologies, Carlsbad, CA, USA) and 0.1% gentamicin
(50 mg/ml: Life Technologies, Carlsbad, CA, USA), and
they were maintained at 37°C in a humid atmosphere of
5% CO2 for 1 and 3 days. The culture medium was
maintained in contact with the support membrane beneath
the explant and changed with freshly prepared warmed
medium every other day. To study the inflammatory role of
the PRGF, explants were cultured in the different
experimental conditions (Table 1) and at least three
replicates from different animals were used for each
condition. No more than one explant from the same eye
was used for each experimental condition.
The explants were cultured in the presence or absence of
10% PRGF from the beginning of the organotypic cultures,
using PRGF obtained from the same animal (autologous),
from another pig (heterologous) or from a human donor. The
human PRGF was added in either an active or inactive form.
Dexamethasone (Dex, 1 μM: Sigma Aldrich, St. Louis, MO,
USA) was also added to the explants or a mixture of three pro-
inflammatory cytokines: IL-1β, IL-6 (10 ng/ml) and TNFα
(20 ng/ml, as recommended in Madeira et al., 2015b:
Sigma-Aldrich, St. Louis, MO, USA). In another
experimental condition these cytokines were inactivated by
adding antibodies against the three cytokines (1 μg/ml, as
recommended in Madeira et al., 2015b): goat anti-IL-1β
and mouse anti-IL-6 (R&D System, Minneapolis, MN,
USA); and rabbit anti-TNFα (Peprotech, London,
United Kingdom) antibodies). In both cases, the cytokines
were also added from the beginning of the culture of the
explants with or without their inhibitors. The explants were
cultures for 1 day and for 3 days. On the other hand, to study
the effect of PRGF on gliosis, proliferation and RGC survival,
selected explants were cultured for 3 days in the presence of
10% human PRGF, which induced a stronger effect on
microglia.
At the end of each experiment, the retinal explants were fixed
overnight in 4% paraformaldehyde (PFA), cryoprotected
overnight at 4°C in 30% sucrose in 0.1 M PB (phosphate
buffer, pH 7.4), and they were then embedded in Tissue-Tek
O.C.T. Compound to obtain cryosections (14 μm) that were
stored at −20°C.
Immunochemistry
The cryostat sections of the explants were immunostained
to detect microglia, gliosis, proliferative cells and RGCs, as
described previously (Vecino et al., 2002). The sections were
washed twice for 10 min with PBS (phosphate buffered
saline, pH 7.4) containing Triton X-100 (0.25%, TX) and
they were incubated overnight with primary antibodies in
PBS-TX containing BSA. The primary antibodies used were
an: anti-Iba1 rabbit antibody (1:2,000, WAKO, Osaka,
Japan), anti-GFAP mouse antibody (1:1,000, Sigma,
Steinheim, Germany), anti-Ki67 rabbit antibody (1:100,
Abcam, Cambridge, England), and anti-Brn3a goat
antibody (1:1,000, Santa Cruz Biotechnology, Santa Cruz,
USA). After two washes with PBS, the sections were
incubated for 1 h with a secondary antibodies at a
dilution of 1:1,000 in PBS-BSA (1%), and with a 1:10,000
dilution of the DAPI nuclear marker (Life Technologies,
Carlsbad, AC, USA). The secondary antibodies used
were anti-rabbit Alexa Fluor 555 or 488, anti-mouse
Alexa Fluor 488 and anti-goat Alexa Fluor 568 (Life
Technologies, Carlsbad, AC, USA). The sections were
washed twice with PBS for 10 min and mounted with
PBS-Glycerol (1:1) before observation under an epifluorescence
microscope.
Cells Quantification
Microglia were analyzed in at least three slides containing a
minimum of six cryostat sections from each explant. The
total extension of the retina analyzed was approximately 10
linear centimetres and this procedure was carried out on at
least three replicates for each condition. The total number of
microglia cells (Iba1) was manually counted and the number
of microglia per linear mm of retina was calculated. In
addition, the number of microglia in the outer nuclear
layer (ONL) was also counted and the proportion of
microglia in this layer of the retina was calculated for each
condition. Similarly, RGC density was also analyzed,
calculated as the mean number of RGCs (Brn3a+) per
linear mm of retina. Cell quantification and images of
Müller and astrocyte gliosis (GFAP), or images of
proliferative cells (Ki67), were obtained on an
epifluorescence microscope (Zeiss, Jena, Germany) coupled
to a digital camera (Zeiss Axiocam MRM, Zeiss, Jena,
Germany), and using the Zeiss Zen software (Zeiss, Jena,
Germany).






10% autologous pig PRGF
10% heterologous pig PRGF
10% human PRGF
10% inactive human PRGF
10% human PRGF + dex
10% human PRGF + anti-cytokines
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Multiplex Cytokine Assays
To detect and quantify the cytokines present in the different
PRGF samples, a multiplex enzyme-linked immunosorbent assay
(ELISA) was used to measure: IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6,
IL-8, IL-10, IL-12p70, IL-13, IL-15, IL-17, IL-23, IFNγ, TNFα,
and TNFβ (Q-Plex™, Human Cytokine Screen, 110996HU,
Quansys Bioscience, Logan, UT, USA). The assay was
performed according to the manufacturer´s instructions,
analyzing 100 μL of the different human and porcine PRGF
samples (pig, inactive pig, human, inactive human and human
plus Dex) in each well of a 98-well plate Q-Plex™. The standards
were measured in duplicate and cytokine concentrations were
calculated using a standard curve. Each individual sample was
assessed in four experimental replicates and the arithmetic
averages were calculated.
Statistical Analyses
Statistical analyses were carried out using the SPSS software
v. 21.0 (IBM), and the mean and standard error was
calculated for each condition. The data from the different
experimental conditions were compared using an analysis
of variance (ANOVA), followed by the Games-Howell test
as there was no homogeneity of the variances according
to a Levene test. For the multiplex cytokine assays, a
non-parametric test was used, the Kruskal-Wallis H test.
The minimum value for significant differences in all the tests
was defined as p < 0.05.
RESULTS
Microglial Migration in Retinal Organotypic
Cultures in the Presence of Plasma Rich in
Growth Factors
Changes in microglial morphology were evident in the retinal
explants (Figure 2), these cells adopting an ameboid shape
distinct to the ramified morphology observed in the control
retina. However, there were no changes in the total number of
microglial cells, with an average of 12.24 ± 0.25 microglial cells/
mm. These microglia were generally located in the inner part of
the retina (Figure 2A), yet the microglia were able to migrate to
the outer plexiform layer (OPL) when maintained in the absence
of PRGF during the culture (Figures 2B,D). However, these cells
migrated to the ONL only when the retinal explants were cultured
in the presence of PRGF (Figures 2C,E).
Since microglial migration is a sign of activation, the
proportion of microglia that migrated to the ONL was
FIGURE 2 | Microglia in a control retina and in organotypic retinal cultures maintained in the presence or absence of human PRGF. Representative images of an
adult pig retina from a control eye (A), or of explants of organotypic cultures maintained in the absence (B,D) or in the presence (C,E) of 10% human PRGF. The explants
were cultured for 1 (B,C) or 3 (D,E) days, labeling the microglial cells with antibodies against Iba1 (red, anti-Iba1 rabbit antibody, 1:2,000, WAKO, Osaka, Japan) and the
nuclei with DAPI (blue). The white arrows point to microglial cells in the ONL: ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer; IPL, inner
nuclear layer; GCL, ganglion cell layer; NFL, nerve fiber layer. Scale bar  100 μm.
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quantified. Initially, the migration of microglia was analyzed
in distinct retinal explants treated with 10% PRGF
(Figure 3).
On day 1, the proportion of microglia in the ONL of the retinal
explants maintained in the presence of 10% PRGF was 0.12 ±
0.07% when autologous PRGF was used, 0.56 ± 0.11% with
heterologous pig PRGF and 1.21 ± 0.4% for human PRGF,
and on day 3 these values increased to 0.53 ± 0.22%, 2.45 ±
0.38% and 3.73 ± 0.57%, respectively. There were no
significant differences between the control explants, in which
there was no microglial migration to the ONL, and those
maintained in the presence of autologous pig or human PRGF
at day 1. However, by day 3 this parameter was significantly
different in explants maintained in the presence of heterologous
pig PRGF (p < 0.05) and human PRGF (p < 0.01) relative to the
controls (the specific p-values are given in the Supplementary
Material).
Quantification of the Cytokines in Plasma
Rich in Growth Factors
Having shown that PRGF can activate microglial cells and
promote their migration, we analyzed the inflammatory
cytokines present in the pig and human PRGF, and in the
heat-inactivated pig and human PRGF. In the different PRGF
samples analyzed, we confirmed the presence of and quantified
the following cytokines: IL-1α, IL-1ß, IL-2, IL-4, IL-6, IL-8, IL-10,
IL-12, IL13, IL-15, IL-17, IL-23, TNFα, and TNFβ (Table 2).
When comparing the cytokine concentrations in pig and
human PRGF, IL-8 was the only cytokine detected at a
FIGURE 3 |Quantification of microglia migration in the presence of autologous and heterologous porcine PRGF or human PRGF. Microglial migration on day 1 and
3 in retinal explants treated with 10% PRGF from the same pig as the retinal explant (autologous) (n  5), from another pig (heterologous) (n  5) or from human blood
(n  5). Microglial migration is represented as the percentage of microglial cells located in the outer nuclear layer (ONL) relative to the total number of microglia: *p < 0.05,
**p < 0.01 relative to the control.
TABLE 2 | Concentration (pg/ml) of the cytokines in porcine and human PRGF
Cytokine Pig PRGF Inactive pig PRGF Human PRGF Inactive human PRGF
IL-1α 8.15 ± 1.67 10.31 ± 0.87 6.34 ± 2.18 6.55 ± 2.39
IL-1ß 14.65 ± 4.93 20.91 ± 7.06 17.03 ± 4.35 17.01 ± 2.54
IL-2 4.58 ± 1.15 6.93 ± 0.13 4.54 ± 0.54 6.17 ± 1.66
IL-4 0.29 ± 0.28 0.87 ± 0.70 0.39 ± 0.32 0.17 ± 0.17
IL-6 3.61 ± 0.49 5.21 ± 0.18 4.24 ± 1.08 3.99 ± 1.14
IL-8a 1.32 ± 0.42 1.24 ± 0.05 29.59 ± 5.73 29.21 ± 3.38
IL-10 4.65 ± 1.47 6.85 ± 2.65 7.21 ± 1.52 4.73 ± 1.61
IL-12 4.96 ± 1.11 5.86 ± 2.11 5.00 ± 3.87 6.71 ± 3.90
IL-13 0.37 ± 0.21 0.29 ± 0.22 0.75 ± 0.75 0.35 ± 0.20
IL-15 2.29 ± 0.49 4.54 ± 1.23 7.09 ± 2.79 6.77 ± 1.92
IL-17 4.59 ± 0.21 2.93 ± 1.02 1.68 ± 0.99 2.88 ± 0.97
IL-23 185.47 ± 43.63 242.71 ± 86.04 283.14 ± 214.27 222.54 ± 158.70
TNFα 4.65 ± 4.25 3.76 ± 3.76 6.61 ± 2.99 1.84 ± 1.84
TNFß 18.40 ± 4.64 14.07 ± 9.76 18.15 ± 14.21 14.88 ± 13.96
asignificant differences between pig (n  5) PRGF and human PRGF (n  3).
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significantly higher concentration in the human than in the pig
PRGF (p < 0.001). In terms of the heat-inactivated pig and
human PRGFs, no differences were found in the cytokine
concentrations relative to the PRGF in either species,
indicating that this heat-inactivation does not affect the
cytokine concentrations (the cytokines activity was not
assessed). However, we did appreciate some variability in the
quantification of cytokines and thus, we analyzed the different
cytokine concentrations between individuals. Significant
differences in the cytokine concentrations of human PRGF
were found between individuals: IL-8, IL-12, IL-13, IL-15, IL-
17, IL-23, and TNFα (p < 0.05). Significant differences among
the cytokines in pig PRGF were also found between different
individuals: IL-1ß, IL-10, IL-15, IL-17, and IL-23 (p < 0.05). The
remaining cytokines were homogeneously distributed between
individuals and no significant differences were found between
them (the specific p-values are given in the Supplementary
Material).
Suppression of Microglial Migration in the
Presence of Plasma Rich in Growth Factors
The suppression of microglia migration was assessed in retinal
explants maintained in the presence of 10% human PRGF,
conditions that induced a higher proportion of microglial
migration. As such, we analyzed the microglial migration in
explants maintained under different culture conditions: adding
cytokines or blocking them with antibodies; adding human
PRGF, heat-inactivating it or adding antibodies against
cytokines; or adding Dex alone or in combination with PRGF
(Figure 4). To test the role of cytokines, we added a mixture of
three major pro-inflammatory cytokines (IL-1β, IL-6 and
TNFα) alone or in combination with antibodies raised
against these cytokines. The microglia migration in the
explants in the presence of cytokines was 0.31 ± 0.16% on
day 1 and 1.14 ± 0.25% on day 3, which fell to 0.24 ± 0.12% on
day 1 and 0.37 ± 0.16% on day 3 in the presence of antibodies
against these cytokines. However, in none of these conditions
were significant differences produced relative to the control
conditions. Fewer microglia migrated in the presence of PRGF
and the anti-cyt mixture, 0.88 ± 0.12% on day 1 and 1.02 ±
0.34% on day 3, and the latter figure in presence of the
cytokine antibodies was significantly lower (p < 0.05) than in
the explants treated with 10% of human PRGF alone on day 3.
The percentage of microglia in the ONL on day 1 was 1.21 ±
0.4% when the explants were exposed to 10% human PRGF and
3.73 ± 0.57% on day 3. When this PRGF was heat-inactivated,
microglial migration decreased to 0.68 ± 0.16% on day 1 and
1.65 ± 0.42% on day 3. In the presence of Dex and PRGF,
microglial migration also decreased to 0.69 ± 0.28% on day 1
and 1.29 ± 0.5% on day 3. However, this apparent decrease in
microglial migration was not significantly different from the
migration in the presence of 10% PRGF alone and nor was it
significantly different from the values in the control explants.
There was a reduction in microglial migration when the PRGF
was heat-inactivated, or when it was used in combination with
Dex or anti-cyt antibodies, although these conditions never
completely suppressed migration. Thus, the pro-migratory
effect of PRGF on microglia appears to be multifactorial and
not only due to the influence of pro-inflammatory cytokines.
FIGURE 4 | Quantification of microglial migration in the presence of human PRGF, inhibiting its inflammatory effect. Microglial migration is represented as the
proportion of microglial cells located in the outer nuclear layer (ONL) relative to the total number of microglia, reflecting the migration in control conditions (n  5), and
in the presence of dexamethasone (Dex: n ), cytokines (cyt, IL-1β, IL-6 and TNFα: n  4), cytokines plus anti-cytokine antibodies (anti-cyt: n  3), with 10% human
PRGF (Human: n  5). The inflammatory effect of PRGF (Human) on microglial migration was inhibited by PRGF heat-inactivation (Human inactive: n  5), or by
adding Dex (n  5) or anti-cytokine antibodies (n  5). Significant differences relative to the control conditions and the presence of human PRGF are shown: *p < 0.05,
**p < 0.01.
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Effect of Plasma Rich in Growth Factors on
Gliosis and Proliferation in Organotypic
Cultures
To determine if PRGF may modify macroglial (astrocytes and
Müller glia) and microglial cells, the distribution of the
cytoskeletal protein GFAP was studied in the retinal explants
to establish the extent of astrocyte and Müller cell activation. In
the control cultures, GFAP labeled astrocytes were detected in the
GCL and NFL, and some Müller cells were labeled for GFAP
(vertical lines in IPL in Figure 5A). The presence of PRGF seemed
to induce the gliosis of Müller cells in the retinal explants
(Figure 5C), although the astrocytes were already activated in
explants in the absence of PRGF (Figure 5B). Thus, the induction
of astrocyte gliosis by PRGF cannot be confirmed.
To study the possible proliferation induced by PRGF we
studied Ki67 as a marker of actively dividing cells. In control
retinas, a few Ki67 labeled cells were detected in an active phase of
the cell cycle (Figure 6), whereas in organotypic cultures
proliferative cells were labeled with the anti-Ki67 antibody in
the presence or absence of human PRGF (Figures 6B,C). These
proliferative cells were rare, even at the edges of the explants
(Figure 6C) and consequently, we cannot confirm that PRGF
increases the rate of proliferation in organotypic cultures of adult
retinas. Considering the position of the proliferative cells and
given that only glial cells can divide in the retina, we conclude that
these proliferative cells were microglia.
Retinal Ganglion Cells Survival in
Organotypic Cultures in the Presence of
Plasma Rich in Growth Factors
Finally, we analyzed the survival of retinal neurons, specifically
RGCs (Figure 7), and relative to the control retinas (20.76 ±
2.3 RGCs/mm), there were significant fewer RGCs in explants
maintained in either the presence (5.44 ± 0.95 RGCs/mm) or
absence (7.05 ± 1.41 RGCs/mm) of human PRGF. However, we
did not find a significant difference in the survival of RGCs in
organotypic cultures maintained in the presence of PRGF and
thus, PRGF does not appear to offer neuroprotection to RGCs in
FIGURE 5 |Gliosis in control retinas and in organotypic retinal cultures maintained in the presence or absence of human PRGF. Representative images of adult pig
retinas from a control eye (n  5:A), or from explants of organotypic cultures maintained in the absence (n  4: B) or presence (n  4:C) of 10% human PRGF. The GFAP
in astrocytes and Müller cells was immunolabeled (green, anti-GFAP mouse antibody, 1:1,000, Sigma, Steinheim, Germany), and the nuclei were labeled with DAPI
(blue): ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer; IPL, inner nuclear layer; GCL, ganglion cell layer; NFL, nerve fiber layer. Scale
bar  100 μm.
FIGURE 6 | Proliferative cells in control retinas and in organotypic retinal cultures maintained in the presence or absence of human PRGF. Representative images of
adult pig retinas from a control eye (n  5: A), and organotypic cultures maintained in the absence (n  4: B) or presence (n  4:C) of 10% human PRGF. The edge of the
explant is also shown (C). The proliferative cells were labeled with antibodies against Ki67 (green, anti-Ki67 rabbit antibody, 1:100, Abcam, Cambridge, England) and the
nuclei with DAPI (blue). The white arrows indicate cells in an active phase of the cell cycle. The edge of the explant is shown to demonstrate the absence of
proliferation (left in picture C): ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer; IPL, inner nuclear layer; GCL, ganglion cell layer. Scale
bar  100 μm.
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explants of adult porcine retinas (the specific p-values are given in
the Supplementary Material).
DISCUSSION
PRGF is a biological supplement which provides a pool of growth
factors that can stimulate and accelerate tissue regeneration, and
hence, it may potentially represent a therapeutic agent to treat
different diseases, including neurodegenerative diseases (Anitua
et al., 2013; Anitua et al., 2014b; Anitua et al., 2015a). In this
study, the influence of PRGF on glial cells and CNS neurons was
assessed in the retina. In organotypic retinal cultures, PRGF
promotes the migration of microglia, a sign of inflammation
that could be due to the cytokines it contains. However, PRGF
does not induce gliosis among astrocytes and partially in Müller
glia, and it does not alter the proliferation of glial cells or modify
RGC survival.
One of the critical steps in the inflammatory response is the
recruitment and migration of immune and inflammatory cells to
inflammatory sites, and in the CNS, microglia are the resident
innate immune cells (Lull and Block, 2010; Omri et al., 2011). In a
healthy retina, microglia are located in the inner part of retina
(Streit et al., 1988; Ling and Wong, 1993; Omri et al., 2011) but
when these cells are activated, they migrate into the sub-retinal
space, as occurs in several retinopathies associated with ocular
inflammation like diabetic retinopathy (Zeng et al., 2008) and
age-related macular degeneration (Combadiere et al., 2007).
Microglial cells were analyzed in organotypic cultures or
explants, a commonly used model of inflammation (Carter
and Dick, 2003; Bauer et al., 2016), assessing the effect of
PRGF. In addition to the microglial migration observed, we
detected a change in their morphology from a ramified to an
ameboid shape in the cultured retinas.
It has been suggested that PRGF could fulfill an inherent anti-
inflammatory role, mediated by NF-kB (Anitua et al., 2014b;
Anitua et al., 2015a). In addition, PRGF could dampen the
inflammatory status of a cell culture model of inflammation
induced by IL-1β and TNFα, significantly decreasing ICAM-1
and COX-2 levels when compared to autologous serum (Anitua
et al., 2016). Thus, to understand how PRGF activates retinal
microglia, the presence of inflammatory cytokines in the PRGF
was quantified. It has been suggested that pro-inflammatory
cytokines are almost absent or limited in PRGF (Anitua et al.,
2015b), although some cytokines have been detected in PRGF: IL-
6 (Masuki et al., 2016), IL-8 (Anitua et al., 2010), IL-4, and TNFα
(Anitua et al., 2012). The concentrations of the cytokines that
were observed in PRGF may be lower than that of some
interleukins in other PRPs (Pochini et al., 2016). The IL-6
concentration in PRGF was similar to the concentrations seen
previously, although IL-1β was not found in PRGF, it was found
in other PRPs with values similar to those identified here (Masuki
et al., 2016). The presence of these and others inflammatory
cytokines in the PRGF was confirmed and corroborated here.
Moreover, the activation of microglia by cytokines was
demonstrated due to the presence of cytokine receptors on
microglia, which express mRNA transcripts for IL-1 receptor I
and II, the IL-6, IL-8, IL-10, IL-12, IL-13, IL-15 receptors, and
TNF receptors I and II (Lee et al., 2002). In addition, IL-6, IL-12
and TNFα can activate microglia (Luo and Chen, 2012) and thus,
the cytokines present in PRGF can themselves trigger an
inflammatory response. This activation would be independent
of the cytokine secretion by the tissue exposed to the PRGF, as
PRGF has been shown to induce the expression of cytokines like
IL-1β, IL-6 or IL-10 (Mozzati et al., 2010). In addition, it has been
suggested that the anti-inflammatory effect of PRGF is due to a
high IL-4 content (Anitua et al., 2012), although the presence of
this and other anti-inflammatory cytokines like IL-10 and IL-13
(Cavaillon, 2001) is weak relative to other cytokines that fulfill an
opposite effect, such as the pro-inflammatory cytokine IL-1β.
In order to dampen microglial migration in the retinal
explants, the PRGF was heat-inactivated prior to exposure to
FIGURE 7 |Quantification of RGCs per millimeter of retina in controls retinas and in explants maintained in the presence or absence of human PRGF. The number of
RGCs per linear mm of retina are shown in control retinas (n  5) and in organotypic cultures at day 3, maintained in the presence (n  4) or absence of 10% human PRGF
(n  4). Significant differences between the controls and explants are indicated: *p < 0.05.
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the explants (Anitua et al., 2014a). We also used Dex to inhibit
inflammation (Tsurufuji et al., 1984) and we used antibodies
against pro-inflammatory cytokines to block their action. The
cytokines selected to mimic a pro-inflammatory environment in
the organotypic cultures were the three major pro-inflammatory
cytokines: IL-1β, IL-6, and TNFα (Taki et al., 2007; Zhang and
An, 2007). It has been demonstrated that reactive microglia
increase their expression and the release of these cytokines in
retinal organotypic cultures (Madeira et al., 2015b). Moreover,
the presence of antibodies against these three cytokines is
sufficient to significantly diminish the number of activated
microglia. However, the neutralization of the pro-
inflammatory cytokines by antibodies did not completely
suppress microglial migration, which could be due to the fact
that these antibodies are from other species (e.g., goat, mouse and
rabbit) and that this might provoke an immune response.
Alternatively, Dex and heat-inactivated PRGF can mildly,
though not entirely, reduce microglial migration. In addition,
the presence of pro-inflammatory cytokines in the cultures does
not mimic the effect of PRGF. These results suggest that there are
other factors in addition to the cytokines implicated in the
activation of microglial migration. It is known that heat-
inactivation maintains the biological activity of PRGF, yet it
fully reduced complement activity and significantly dampened
the presence of IgE (Anitua et al., 2014a). However, in addition to
cytokines, IgM and IgG are also present in the heat-inactivated
PRGF (Anitua et al., 2014a), and IgG increases microglial
activation due to the expression of high affinity IgG receptor
(FcαRI: Orr et al., 2005). Thus, complement and
immunoglobulins, as well as cytokines, could participate in the
activation of the retinal inflammatory response. Moreover, Dex
did not totally block the effect of the cytokines in the medium
(Pereiro et al., 2018), confirming that microglial activation is
triggered by different factors.
By contrast, microglial migration is higher when the PRGF is
heterologous (the donor is from a different animal from that
which donates the retina) in comparison to the migratory effect
when the PRGF is autologous. In addition, human PRGF (when
the donor is from a different species) induces stronger microglial
activation than the pig PRGF in the porcine retina and this could
be due to the presence of the pro-inflammatory cytokine IL-8,
which is significantly more abundant in the human PRGF.
Moreover, the presence of other receptors in microglial cells,
such as toll like receptors (TLR) that respond to self and non-self
activators (Shastri et al., 2013), could be implicated in the
activation of microglia when the PRGF is not autologous or it
is from another species. Therefore, patients suffering from
autoimmune diseases, or patients in which their own PRGF is
not as effective as expected, should receive PRGF from a donor.
Moreover, this heterologous PRGF must be inactivated or
combined with an anti-inflammatory treatment in order to
mitigate the inflammatory response that might be initiated.
In terms of gliosis, it was suggested that PRGF decreases
astrocyte reactivity (Anitua et al., 2013; Anitua et al., 2014b).
However, we found that human PRGF initiated an inflammatory
response activating porcine microglial migration, inflammation
that could activate astrocytes and Müller cells. In gliosis,
macroglial cells can divide and become hypertrophic,
producing long, thick processes, as well as overexpressing
GFAP (Lee et al., 2002; Vecino et al., 2016). Nevertheless, in
our model of retinal explants astroglia are activated per se and an
increase in gliosis was not evident in astrocytes in the presence of
PRGF. However, a mild increase in Müller cell gliosis was seen in
the presence of PRGF. In summary, some heterogeneity in GFAP
expression was found in the organotypic cultures, regardless of
PRGF. It is known that biomechanical tension is a vital factor in
maintaining retinal tissue integrity in organotypic cultures, and
stretched retinal explants displayed no signs of gliosis, as well as
increased neuronal survival and preservation of retinal
architecture (Taylor et al., 2013). Therefore, some variability in
the tensile strength of explants may explain the results obtained.
The proliferative effects of PRGF were first demonstrated in
dentistry, oral implantology, orthopedics, sports medicine and the
treatment of skin disorders (Anitua et al., 2010). This proliferative
effect is due to the growth factors in PRGF, such as IGF-1, PDGF or
FGF, powerful stimulators of cell replication/proliferation (Anitua
et al., 2009; Vahabi et al., 2015). In ophthalmology, intravitreal
injection of PRP induces proliferation of retinal fibroblast-like cells
and it was used as amodel of proliferative vitreoretinopathy (Pinon
et al., 1992). Moreover, different platelet preparations produce
similar proliferative effects on immortalized human Müller cells
(MIO-M1), in addition to stimulating their migration (Burmeister
et al., 2009). However, our results do not demonstrate that PRGF
induces the proliferation of glial cells. This could be due to
proliferation being inhibited by cell-cell contact, which might
occur in many cells (Ribatti, 2017), as the retinal explant used
here preserves retinal architecture and the cells are in contact in a
physiological manner. However, in cultured Müller cells, the
application of PRGF increases the Müller cell number (Ruzafa
et al., 2021). It is possible that we could not detect Müller
proliferation in our explants due to the preservation of retinal
structure, as we have shown in vitro. It may be possible that Müller
glia proliferation underlies the structural restauration of the retina
in patients with macular hole after injecting autologous PRGF. On
the other hand, microglia reaction is beneficial by the acquisition of
new functions before the alteration of their homeostatic roles
(Sierra et al., 2013; Hemonnot et al., 2019). These beneficial
properties of microglia could positively affect the restoration of
the macular hole in patients.
In the CNS, microglia immediately migrate to sites of tissue
damage (Nimmerjahn et al., 2005). By contrast, macroglia do not
migrate but they may die in the focal point of severe lesions, or they
may become reactive and hypertrophic, in some cases proliferating
(Bardehle et al., 2013; Burda and Sofroniew, 2014). PRGF appears
to promote microglial migration with only mild signs of gliosis and
with no increase in the rate of glial cell proliferation, and
interspecific PRGF induces mild signs of inflammation, which
could be easily reverted by inactivating the PRGF or combining it
with anti-inflammatory drugs or antibodies against cytokines.
However, in vivo studies will be required to confirm these
results as the behavior of the cells could differ.
Previous studies suggested that PRGF induces
neuroprotection by activating anti-apoptotic PI3K/Akt
signaling and/or diminishing caspase-3 levels (Anitua et al.,
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2013). Moreover, it has been suggested that PRGF induces
neuroprotection in association with a down-regulation of the
activated microglial cell number and a significant decrease of pro-
inflammatory mediators (Anitua et al., 2015a). Studies of other
neurodegenerative diseases, such as AD (Anitua et al., 2013;
Anitua et al., 2014b) and Parkinson’s disease (Anitua et al.,
2015a), show that cell survival was enhanced by PRGF in
primary neuronal cultures, and the number of degenerating
neurons was reduced. However, PRGF activated microglia here
and we did not find changes in RGC survival. The concentrations
of PRGF used here were 10%, as used when studying the effects of
human PRGF in mouse models (Anitua et al., 2013; Anitua et al.,
2014b). Thus, the concentration and interspecies interactions
here are unlikely to affect neuroprotection. By contrast, it was
suggested that thrombin-activated PRP releases glutamate, and
when it is applied to neuronal cultures it is neurotoxic (Bell et al.,
2014). Moreover, some of the morphogens or growth factors
present in PRP, like PRGF, could have an adverse effect on
neurons, such as TGF-β1 that exerts negative effects on axon
growth in rat brain-spinal cord co-culture (Takeuchi et al., 2012).
Such results could explain why we did not find a neuroprotective
role of PRGF in the retinal explants.
Although PRGF has been successfully used in different
medical and surgical specialties, and there is extensive data
indicating that PRP induces tissue regeneration, many of these
studies are not sufficiently rigorous or controlled, and their data is
often limited. Indeed, other studies have produced contrasting
results (Kuffler, 2015). Currently, autologous PRP injections have
been used as pilot treatments for some retinal lesions (Nadal et al.,
2012; Arias et al., 2019). Although structural recovery of the
retina may be achieved (for instance closure of a macular hole), a
functional recovery might be limited by the potential increase in
inflammatory reaction which may have deleterious for the cells
and be responsible for several complications like focal macular
epithelial pigmentary hypertrophy, development of epiretinal
membrane and cataract progression among other (Minihan
et al., 1997; Cheung et al., 2005; Nugent and Lee, 2015).
Therefore, the impact of PRGF is not fully understood and the
applications of PRGF in ophthalmology must be analyzed in
more detail. Differences in the levels of the factors present in
PRGF and in other blood-derived products may explain the
variability in the results obtained in different studies (Vahabi
et al., 2015), as evident through the significant differences in the
cytokine concentrations between samples observed here. Thus,
further animal and clinical studies should be performed to clarify
the properties of PRGF.
CONCLUSION
PRGF has been used in ophthalmology to treat persistent
macular holes and recurrent retinal detachment, although the
mechanisms through which PRGF works in the CNS remain
unclear. In retinal organotypic cultures, PRGF induces
microglial activation, an inflammatory response that may be
due to the presence of inflammatory cytokines. However, we
cannot rule out the possible positive effect of microglial cells in
repairing the retina, as suggested. Autologous PRGF induces
weaker signs of inflammation that heterologous PRGF and that
from other species, and this microglia activation may be
mitigated. Moreover, PRGF does induce partial gliosis,
although it does not appear to induce glial proliferation or
RGC neuroprotection. Thus, while PRGF could be a good
candidate to stimulate and accelerate tissue regeneration,
more studies will be necessary to clarify its effects on the
nervous and immune systems.
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